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268 D.E.M. Soud et al.Measurements: Plasma concentration of sTREM-I in the three groups was compared. Sensitivity,
speciﬁcity and predictive values of sTREM-I were compared with the results of procalcitonin. Also,
microbiological cultures for infection were examined.
Results: There was a highly signiﬁcant increase in the level of sTREM-I in patients with sepsis
(475.7 ± 97.9 for HISS group and 398.5 ± 103.9 for LISS group) than in the control group
(102.7 ± 42.6). Also, there was a highly signiﬁcant increase in its level in patients with sepsis
(475.7 ± 97.9 for HISS group and 398.5 ± 103.9 for LISS group) in comparison to those with
SIRS (189.3 ± 26.5 for HISS group and 177.2 ± 40 for LISS group). There was a highly signiﬁcant
increase in procalcitonin in septic patients in comparison to SIRS group (3.9 ± 0.86 for LISS and
7.1 ± 1.4 for HISS). The sensitivity and speciﬁcity of sTREM-I were signiﬁcantly higher than those
of procalcitonin (94.7% and 91.8% for sTREM-I and 84.2% and 75.4% for procalcitonin).
Conclusion: The soluble TREM-I was a sensitive and speciﬁc marker for early differentiation of
infection from SIRS in trauma patients.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Trauma is one of the main causes of death among people
worldwide. Mortality occurs early after trauma (ﬁrst hits)
caused by head injury, severe organ injury or bleeding, fol-
lowed by a period in which the cause of death may be due to
hypoxia, hypovolemia or severe head trauma [1]. Second hits
occur in the latter times after trauma causing high incidence
of morbidity and mortality caused by infections, ischemian
reperfusion or operations [2].
Massive injury leads to activation of immune system and
inﬂammatory immune response (systemic inﬂammatory re-
sponse syndrome, SIRS) with stimulation of many cells in
the body including monocytes, macrophages and T-helper-1
lymphocytes [2].
This immune system stimulation leads to systemic release of
both pro-inﬂammatory (TNF, IL1, IL6, IL8 and IL12) and anti-
inﬂammatory cytokines (IL10) or mediators [3].
The function of immune system is to recognize, activate,
discriminate, regulate and eradicate the introducing exogenous
and pathogenic signals [2]. In injured patients, the neuroendo-
crine response with production of adrenocorticosteroids and
catecholamines leads to an increase in the heart rate, respira-
tory rate, fever, and leukocytosis [4].
Sepsis is a major cause of morbidity and mortality in
trauma patients. There are many risk factors for sepsis in
traumatized patients including:
(a) Type of injury (penetrating or non-penetrating).
(b) The host response (age, sex, immune response, diabetes
mellitus and trauma severity).
(c) The clinical response to instrumentation, blood transfu-
sion, ﬂuids and splenectomy [4].
Clinical and laboratory signs of systemic inﬂammation are
neither sensitive nor speciﬁc for the diagnosis of sepsis espe-
cially when microbiological cultures are still negative in cases
of antibiotic pretreatment or inadequate sampling [5].
Regular use of broad spectrum antibiotics in patients with-
out infection is harmful, facilitating colonization, superinfec-
tion, multidrug-resistant bacteria, toxicity and increases the
cost [6].
There is a suggestion that early identiﬁcation and treatment
of severe sepsis and septic shock improve outcomes [7].So, there is a need for clinical or laboratory tests to differ-
entiate between sepsis and non-infectious inﬂammatory disor-
ders. Elevated levels of inﬂammatory mediators and acute
phase reactants are found in sepsis, but none are speciﬁc for
infection and increased in other inﬂammatory conditions with-
out infection [5].
There are delays of 24–48 h till deﬁnitive quantitative
microbial culture results are reached. So, there are many stud-
ies on biologic markers in an effort to improve early differen-
tiation of systemic inﬂammatory response syndrome from
infection in trauma patients [8].
The biological marker of sepsis would fulﬁll some criteria:
It must be speciﬁc, sensitive and able to be measured early
and easily [5].
Procalcitonin is considered a speciﬁc marker for severe bac-
terial infection and differentiate patients who have sepsis from
those having SIRS [9].
Procalcitonin is a propeptide of calcitonin produced in the
thyroid, normally present in blood at a concentration of
<1 ng/ml and expressed as part of the host’s inﬂammatory re-
sponse to a variety of insults e.g. trauma, pancreatitis, infec-
tion, burn and surgery [10]. It has been shown to be superior
to IL6 and C-reactive protein (CRP) in diagnosis [11].
Also, it is more useful in the follow-up of the cases of sepsis
and as a prognostic marker but, there are some limitations for
its use e.g. peak plasma concentrations of PCT are reached
within 12–24 h of the stimulus [12], PCT half-life in circulation
is 24–30 h even in renal failure [13]. So, serial tests can indicate
changes in the inﬂammatory status of the patient, also the test
may not be available.
Triggering receptor expressed on myeloid cells (TREM)-1,
a recently discovered receptor of immunoglobulin superfamily,
activates neutrophils and monocytes/macrophages [14].
Its expression is upregulated on phagocytic cells in the pres-
ence of bacteria or fungi. So, its presence in the plasma medi-
ates the acute inﬂammatory response to microbial products
[15].
Conversely, sTREM-1 is not upregulated in samples from
patients with non-infectious inﬂammatory conditions like pso-
riasis, immune complex-mediated vasculitis and ulcerative coli-
tis. So, this receptor is present only in the cases of infection
[16].
The technique used for detection of sTREM-I can be per-
formed within 3–4 h and produce information before blood
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individual samples [15].
This recent marker has not been evaluated in trauma
patients before. So, the purpose of this work was to evalu-
ate whether sTREM-I concentration can differentiate be-
tween traumatized patients with SIRS from those with
infection.2. Patients and methods
This study was carried out in the Emergency Surgical Depart-
ments, Intensive Care Unit of Anesthesia with the aid of the
Microbiology and Immunology Department, Faculty of
Medicine, Zagazig University Hospitals between January and
September 2010.
The study was conducted on 80 trauma patients, 27 females
and 53 males, their ages ranged from 16 to 50 years.
Patients were enrolled in the study if they had two or more
of the following signs of systemic inﬂammatory response syn-
drome: temperature >38 C or <36 C, pulse rate >90 beats/
min, respiratory rate >20 breaths/min or hyperventilation
with partial pressure of arterial carbon dioxide (PaCO2)
<32 mmHg or white blood cell count >12.0 · 103 cm1 or
<4.0 · 103 cm1 or >10% immature cells [17].
Trauma patients were excluded if their ages were out of the
study range, immunocompromized, leukopenic (white blood
cells <1.0 · 103 cm1) or neutropenic (polymorphonuclear
granulocyte count <0.5 · 103 cm1), burn and diabetic pa-
tients. Also, patients discharged early before completion of
the study period (14 days) or failed to survive were excluded
from the study.
The control group was 10 trauma patients with ISS P25
but without evidence of SIRS. Then, the study group was 70
patients, classiﬁed into two groups according to the injury
severity score (ISS) [18] into low injury severity score group
(LISS group) in which ISS was between 9 and 25 and the high
injury severity score group (HISS group) in which the ISS was
>25. Written informed consent from patients or their relatives
was obtained.
The patient age, sex, Glasgow coma scale, ISS, Acute
Physiology and Chronic Health Evaluation (APACHE) II
score was recorded [19].
Also, the vital signs, respiratory rate, routine blood tests
including procalcitonin level, microbiological culture, soluble
TREM-I measurement, discharge or death during the follow-
up period (14 days) were recorded.
The research team did not interfere with the job of the
attending doctors in their order of antimicrobial therapy or
microbiological tests.
The diagnosis of infection was depending on the presence of
SIRS, laboratory, microbiological tests and the treating
doctors.
Different clinical samples were collected according to the
suspected site of infection (e.g. wound swab, pus, urine, spu-
tum or tracheobronchial aspirate, intravenous catheter and
blood). All specimens were cultured on different microbiolog-
ical media (nutrient, blood, CLED and MacConkey agar)
(Oxoid). The isolated organisms were identiﬁed by their colony
morphology, microscopic appearance and by different bio-
chemical tests [20].2.1. Soluble TREM-1 measurements
Five milliliters of venous blood was withdrawn and EDTA was
used as anticoagulant. Plasma was collected by centrifugation
for 15 min at 1000 · g within 30 min of collection, aliquot and
stored at 20 C until use in the assay. The sTREM-I concen-
tration in plasma samples was measured with a Quantikine
Human TREM-1 immunoassay kit (R&D Systems, Minneap-
olis, MN) according to the manufacturer’s instructions. This
assay employs the quantitative enzyme immunoassay tech-
nique. Brieﬂy, a monoclonal antibody speciﬁc for TREM-1
has been pre-coated onto a microplate. Standards and samples
were pipetted into the wells and any TREM-1 was added to the
wells. Following a wash to remove any unbound antibody-
enzyme reagent, a substrate solution was added to the wells
and color develops in proportion to the amount of TREM-1
bound in the initial step. The color development is stopped
and the intensity of the color was measured.
3. Statistical analysis
Data were checked, entered and analyzed by using SPSS (ver-
sion 15). Data were expressed as number and percentage or
mean ± SD as appropriate. Chi-squared (v2), t-test and
ANOVA test were used when appropriate. Validity of the
markers was calculated.
p< 0.05 was considered statistically signiﬁcant. p< 0.001
was considered highly signiﬁcant.4. Results
From January to September 2010, 80 trauma patients, 27
females and 53 males, were enrolled in this study.
The demographic data and the clinical proﬁle of the study
groups and the control group were shown in Table 1.
The mean values ± SD for the injury severity score were
36.5 ± 8.2, 17.9 ± 2.4, and 34.2 ± 6.9, respectively. The
APACHE-II score of the studied groups were 15.9 ± 1.7,
10.8 ± 1.16 and 17.2 ± 1.6, respectively. The mortality rate
was 11.25% (all 9 patients) as shown in Table 1.
The other clinical characteristics did not differ signiﬁcantly
between patients with LISS and those with high ISS (Table 1).
Types of injury in patients (head, chest, orthopedic, abdom-
inal or miscellaneous trauma) were expressed as number and
percentage (Table 2). There was no signiﬁcant difference be-
tween patients regarding the types of injury.
Microbiological cultures demonstrated sepsis in 19 patients
out of 70 patients. Sepsis was caused by Gram-negative bacte-
ria in 10 patients (52.63%), by Gram-positive bacteria in 7
patients (36.84%) and by fungi in 2 patients (10.53%).
Table 3 represented the source of infection in septic trauma
patients after the microbiological cultures expressed as number
and percentage. Abdominal wounds represented high inci-
dence of infection (31.6%) followed by the chest (26.3%).
As regards the soluble TREM-I and the procalcitonin levels
(Table 4), there was a highly signiﬁcant increase in their levels
in patients with sepsis than those of the control group.
Also, there was a highly signiﬁcant increase in their levels in
systemic inﬂammatory response syndrome groups than those
of the control group and there was a highly signiﬁcant increase
Table 1 Demographic data and clinical proﬁles.
Control group (n= 10) LISS group (625) (n= 33) HISS group (>25) (n= 37) p
Age 33.6 ± 9.6 (18–50) 30.9 ± 9.3 (16–50) 29.3 ± 9.4 (16–50) 0.4
Sex (male/female) 7/3 20/13 26/11
Temperature 37.2 ± 0.5* (36.5–37.5) 38.5 ± 0.4 (38–39) 38.6 ± 0.37 (38–39) <0.001
Leukocytic count (·103 cm1) 9.9 ± 1.6* (7–12) 12.7 ± 0.8 (12–14.6) 13.2 ± 0.8 (12–14.6) <0.001
GCS (points) 12.7 ± 1.16 (11–14) 12.3 ± 0.9 (12–14) 11.1 ± 1.2* (10–13) <0.001
ISS (points) 36.5 ± 8.2 (25–50) 17.9 ± 2.11* (15–22) 34.2 ± 6.9 (27–50) <0.001
APACHE II (points) 15.9 ± 1.7 (13–18) 10.8 ± 1.16* (9–12) 17.2 ± 1.6 (15–20) <0.001
Mortality rate (No., %) 1 (10%) 3 (8.6%) 5 (11.1%) 0.9
Data were expressed as mean ± SD or number and percentage as appropriate. p> 0.05 is non-signiﬁcant and p< 0.001 is highly signiﬁcant.
LISS, low injury severity score group; HISS, high injury severity score group; GCS, Glasgow coma scale; ISS, injury severity score.
* Highly signiﬁcant difference with the other two groups.
Table 2 Types of injury of different studied groups.
Control group (n= 10) LISS group (n= 33) HISS group (n= 37) p
No. % No. % No. %
Head injury 3 30 9 27.3 13 35.1 0.77
Chest trauma 1 10 4 12.1 5 13.5 0.95
Orthopedic trauma 2 20 10 30.3 6 16.2 0.36
Abdominal trauma 4 40 8 24.2 11 29.7 0.61
Miscellaneous – – 2 6.1 2 5.4 0.73
Data were expressed as number and percentage. p> 0.05 is non-signiﬁcant.
LISS, low injury severity score group; HISS, high injury severity score group.
Table 3 Sources of infection according to the microbial
cultures.
Source No. %
Abdomen 6 31.6
Chest 5 26.3
Urine 3 15.8
Wound 2 10.5
IV catheter 2 10.5
Blood 1 5.3
Data were expressed as number and percentage.
Table 4 sTREM-I and procalcitonin levels.
Control (n= 10) LISS group (n=
SIRS (n= 27)
sTREM-I (pg/ml) 102.7 ± 42.6** 177.2 ± 40+,a
Procalcitonin (ng/ml) 0.9 ± 0.5** 1.61 ± 0.6+,a
** The control group is highly signiﬁcant in comparison to the other gro
+ SIRS versus sepsis in the same group (p< 0.001, highly signiﬁcant).
a SIRS in LISS group versus SIRS in HISS group (p< 0.05, signiﬁcan
b Sepsis in LISS group versus sepsis in HISS group (p< 0.001, highly
Table 5 Validity of sTREM-I and procalcitonin in detection of inf
Sensitivity (%) Speciﬁcity (%)
sTREM-I (pg/ml) 94.7 91.8
Procalcitonin (ng/ml) 84.2 75.4
270 D.E.M. Soud et al.in their levels in septic patients in comparison to those with
systemic inﬂammatory response syndrome.
It was observed that their levels were higher in patients with
high ISS than the low ISS patients (Table 4).
Also, it was observed that the rate of systemic inﬂammatory
response syndrome in trauma patients (51 patients) was higher
than the rate of sepsis in them (19 patients only) and there were
precipitating factors for the infection e.g. penetrating wounds,
exposure to operations, artiﬁcial ventilation, urinary catheter,
etc.).
Table 5 showed the validity of sTREM-I and procalcitonin
in the detection of infection, there was a signiﬁcant increase in33) HISS group (n= 37)
Sepsis (n= 6) SIRS (n= 24) Sepsis (n= 13)
398.5 ± 103.9b 189.3 ± 26.5+ 475.7 ± 97.9
3.9 ± 0.86b 2.3 ± 0.7+ 7.1 ± 1.4
ups.
t).
signiﬁcant).
ection.
+ve predictive value (%) ve predictive value (%)
78.3 98.2
51.6 93.9
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TREM-I in comparison to the procalcitonin (84.2% and
45.4%, respectively).
The cut-off value of sTREM-I was 254 pg/ml. The positive
predictive value for sTREM-I was 78.3% and its negative pre-
dictive value was 98.2%. So, it is more sensitive in the early
detection of infection.5. Discussion
The result of this study showed the value and accuracy of rapid
measurement of sTREM-1 level in early differentiation be-
tween patients with infection and those with systemic inﬂam-
mation without infection as in trauma patients.
As shown in the result of this study, there was a highly sig-
niﬁcant increase in sTREM-I level in septic patients than those
with systemic inﬂammatory response syndrome and the con-
trol group. It was noticed that the sTREM-I level was higher
in high injury severity score group than the low injury severity
score one.
These results were in accordance with the result of Gibot
[21] who improved that there is a signiﬁcant increase in both
membrane bound TREM-1 and its soluble form during sepsis.
sTREM-I is highly expressed in inﬂammatory lesions
caused by infectious agents e.g. bacteria and fungi but not in
non-infective lesions [16].
The results of Rivera and Minei [17] also go hand in hand
with the results of this study because they found that in surgi-
cal intensive care unit, patients with infection had signiﬁcant
increase in sTREM-I than patients with SIRS with 96% sensi-
tivity and 91% speciﬁcity.
And these results were in agreement with the results of Gi-
bot et al. [8] who found that the presence of sTREM-I by itself
in broncho-alveolar-lavage ﬂuid was more efﬁcient than any
clinical ﬁndings or laboratory values in identifying the pres-
ence of bacterial or fungal pneumonia in mechanically venti-
lated patients.
The accuracy of sTREM-I in the detection of infection has
been observed in pneumonia [8], pancreatitis [22] and pleural
effusions [23].
So, rapid assessment of sTREM-1 level in plasma is consid-
ered an effective tool for the early detection of infection.
Also, this study showed the high sensitivity and speciﬁcity
of sTREM-I than that of procalcitonin in the detection of
infection, because the procalcitonin level already increases in
trauma patients without infection depending on the severity
of injury [24].
In trauma patients without infection, PCT levels will be de-
creased with time, but if there is infection, PCT level will show
higher initial level with sustained elevation in its level [24].
So, serial measurements of PCT level has an important role
as a prognostic marker.
In this study, it was observed that higher PCT level was per-
sistent in septic patients but decreased in patients with systemic
inﬂammatory response syndrome during the follow up period
(14 days).
Early detection of infection has a major beneﬁt on the clin-
ical course, management and the outcome of patients. The
diagnosis of infection is not done by a single test, but it needs
medical history, physical examination, biological indicator and
microbiological tests [15].So, sTREM-1 is considered a reliable marker for the early
detection and differentiation of patients with sepsis from those
with inﬂammation of non infectious origin.
The clinical role of sTREM-1 comes when its level is low,
allowing the physician to stop using antibiotics till the results
of culture are ready and protecting the patient from unneces-
sary use of antibiotics, so may be helpful in clinical decision
during the management course of critically ill patients.
6. Conclusion
The level of soluble triggering receptor expressed on myeloid
cell-I showed an early signiﬁcant increase in the cases of bacte-
rial or fungal infection. So, it was a sensitive and speciﬁc mar-
ker for differentiating infection from systemic inﬂammatory
response syndrome in trauma patients.
7. Limitations
sTREM-I was measured only once. So, we cannot evaluate
sTREM-I as a prognostic marker. So, there is a need for serial
measurements of sTREM-I. Also, it is needed to assess the fac-
tors that increased the incidence of infection in trauma pa-
tients, and sTREM-1 did not detect viral infection.
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